Role of SM22 in the differential regulation of phasic vs. tonic smooth muscle.
Satish Rattan, Mehboob Ali
Index: Am. J. Physiol. Gastrointest. Liver Physiol. 308(7) , G605-12, (2015)
Full Text: HTML
Abstract
Preliminary proteomics studies between tonic vs. phasic smooth muscles identified three distinct protein spots identified to be those of transgelin (SM22). The latter was found to be distinctly downregulated in the internal anal sphincter (IAS) vs. rectal smooth muscle (RSM) SMC. The major focus of the present studies was to examine the differential molecular control mechanisms by SM22 in the functionality of truly tonic smooth muscle of the IAS vs. the adjoining phasic smooth muscle of the RSM. We monitored SMC lengths before and after incubation with pFLAG-SM22 (for SM22 overexpression), and SM22 small-interfering RNA. pFLAG-SM22 caused concentration-dependent and significantly greater relaxation in the IAS vs. the RSM SMCs. Conversely, temporary silencing of SM22 caused contraction in both types of the SMCs. Further studies revealed a significant reverse relationship between the levels of SM22 phosphorylation and the amount of SM22-actin binding in the IAS and RSM SMC. Data showed higher phospho-SM22 levels and decreased SM22-actin binding in the IAS, and reverse to be the case in the RSM SMCs. Experiments determining the mechanism for SM22 phosphorylation in these smooth muscles revealed that Y-27632 (Rho kinase inhibitor) but not Gö-6850 (protein kinase C inhibitor) caused concentration-dependent decreased phosphorylation of SM22. We speculate that SM22 plays an important role in the regulation of basal tone via Rho kinase-induced phosphorylation of SM22.Copyright © 2015 the American Physiological Society.
Related Compounds
Related Articles:
Functional consequence of the MET-T1010I polymorphism in breast cancer.
2015-02-20
[Oncotarget 6(5) , 2604-14, (2015)]
Immunomodulation by the Pseudomonas syringae HopZ type III effector family in Arabidopsis.
2014-01-01
[PLoS ONE 9(12) , e116152, (2014)]
Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy.
2015-05-01
[Biomaterials 51 , 1-11, (2015)]
2015-04-01
[J. Pineal Res. 58(3) , 310-20, (2015)]
2015-04-22
[J. Ethnopharmacol. 164 , 265-72, (2015)]